Aurinia Pharmaceuticals Announces New and Refined Method of Use Patent for LUPKYNIS in the Treatment of Lupus Nephritis Issued by United States Patent and Trademark Office (Businesswire) - Apr 11, 2023 - "Aurinia Pharmaceuticals...today announced that the United States Patent and Trademark Office (USPTO) has issued a new and refined method of use patent titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. Aurinia's newly issued U.S. Patent (No. 11,622,991) reflects the unique and proprietary dosing regimen of its currently marketed product, LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with mycophenolate mofetil (MMF) and corticosteroids using eGFR as a method of pharmacodynamically dosing the product in patients with lupus nephritis. The newly issued patent provides coverage that supplements Aurinia's existing U.S. Patent No. 10,286,036, which is listed in the Orange Book and claims an FDA-approved method of using LUPKYNIS. TThis patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037."
Patent • Immunology • Lupus Nephritis
|